* The S&P 500 fell 0.3% on Thursday, September 5th. * Soft private payroll data added to concerns about the labor market. * McKesson shares plummeted after announcing plans to sell its Canada-based Rexall and Well.ca businesses.

The company’s guidance for the second quarter came in at $1.50 per share, below the $1.60 consensus estimate. This shortfall was attributed to a combination of factors, including supply chain disruptions, inflation, and increased competition. These factors have been impacting the pharmaceutical and medical supply industry as a whole. McKesson’s decision to sell its Canadian businesses is a strategic move aimed at streamlining its operations and focusing on its core competencies. The sale of Rexall and Well.ca will generate $1.5 billion in proceeds, which will be used to invest in growth areas like oncology and biopharma services.

The surge in Dollar Tree’s stock price was driven by a positive earnings report and a strong outlook for the company’s future. The company’s earnings report showed a significant improvement in its profitability, with net income rising to $1.1 billion in the second quarter of 2023, compared to $700 million in the same period last year. This marked a 67% increase in net income. This impressive performance was attributed to a combination of factors, including higher sales, lower operating expenses, and a favorable pricing environment.